Few companies stand better poised than Beam Therapeutics to reap the first fruits of the FDA’s promised flexibility toward cell and gene therapies. | Riding a regulatory win for its base editing ...

Futuristic 3D cubes showing DNA base pairs and a double helix. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive ...

Beam stock launched Monday after the company reached a deal with the Food and Drug Administration for its gene-editing drug, BEAM-302.

Beam Therapeutics focuses on base editing technology, which allows for precise changes at the DNA level and potentially reduces off-target effects. Base editing has the versatility to correct a wide ...

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Beam Therapeutics Inc. (NASDAQ:BEAM) stands ...

Beam Therapeutics’ experimental gene-editing therapy for sickle cell disease now has its first cut of patient data showing signs of treating the rare blood disorder in a way that could differentiate ...

Beam Therapeutics Inc. pivots from platform story to execution-driven thesis, with regulatory clarity accelerating BEAM-302 and Risto-cel in 2026. Learn more about BEAM stock here.

Beam Therapeutics BEAM is engaged in developing investigational gene therapy candidates that are currently in early-to-mid-stage development for treating certain hematology and genetic diseases. The ...

A Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has early signs of efficacy along with safety data that ease some concerns about ...

On Monday, Beam Therapeutics Inc. (NASDAQ:BEAM) announced initial safety and efficacy data from its Phase 1/2 trial of BEAM-302, establishing clinical proof-of-concept as a potential treatment for ...

BEAM-101 Data Highlight Precision of Base Editor with No Off-Target Editing Observed; Will Support Planned IND Submission in the Second Half of 2021 In Vivo Data from Makassar Base Editing Program ...